Second Sight Medical Products (Second Sight Medical Products) Retained Earnings : $-333.87 Mil (As of Jun. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Second Sight Medical Products Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Second Sight Medical Products's retained earnings for the quarter that ended in Jun. 2022 was $-333.87 Mil.

Second Sight Medical Products's quarterly retained earnings declined from Dec. 2021 ($-328.59 Mil) to Mar. 2022 ($-330.80 Mil) and declined from Mar. 2022 ($-330.80 Mil) to Jun. 2022 ($-333.87 Mil).

Second Sight Medical Products's annual retained earnings declined from Dec. 2019 ($-304.78 Mil) to Dec. 2020 ($-319.66 Mil) and declined from Dec. 2020 ($-319.66 Mil) to Dec. 2021 ($-328.59 Mil).

Second Sight Medical Products Retained Earnings Historical Data

The historical data trend for Second Sight Medical Products's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Second Sight Medical Products Retained Earnings Chart

Second Sight Medical Products Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Retained Earnings

Get a 7-Day Free Trial

-234.38

-269.47

-304.78

-319.66

-328.59

Second Sight Medical Products Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Retained Earnings	Get a 7-Day Free Trial															-324.80	-327.30	-328.59	-330.80	-333.87

Second Sight Medical Products Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Second Sight Medical Products (NAS:EYES) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Second Sight Medical Products (Second Sight Medical Products) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Second Sight Medical Products Inc (NAS:EYES) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

13170 Telfair Avenue, Sylmar, CA, USA, 91342

Website

https://www.secondsight.com

Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States.

Executives

Lisa Ellen Porter	officer: Chief Medical Officer	778 CORDILLERAS AVE, SAN CARLOS CA 94070
Donald Dwyer	officer: Chief Business Officer	54 CHERRY FARM LANE, WEST CHESTER PA 19382
Truc Le	officer: COO	1905 WEST RED FOX ROAD, SANTA ANA CA 92704
Adam Mendelsohn	director, officer: CEO	C/O 5858 HORTON ST. SUITE 280, EMERYVILLE CA 94608
Brigid Makes	officer: CFO	20245 SW 95TH AVENUE, TUALATIN OR 97062
Gregg Williams	director, 10 percent owner	PO BOX 200, WALLED LAKE MI 48390-0200
Wilford Dean Baker	director	200 FLYNN ROAD, CAMARILLO CA 93012-8790
Larson Alexandra L.p.	director	3797 BURNING TREE DRIVE, BLOOMFIELD HILLS MI 48302
Scott Dunbar	officer: Acting CEO	13170 TELFAIR AVENUE, SYLMAR CA 91342
Edward Jonathon Sedo	officer: Controller	4485 FORESTGLEN CT, MOORPARK CA 93021
Jonathan Will Mcguire	director, officer: Chief Executive Officer	96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Jessy Dana Dorn	officer: VP-Clin & Scientific Affairs	12744 SAN FERNANDO RD. SUITE 400, SYLMAR CA 91342
Edward David Randolph	officer: Vice President Manufacturing	12744 SAN FERNANDO ROAD, BLDG. 3, SYLMAR CA 91342
Matthew J Pfeffer	director
Aaron Mendelsohn	director	224 15TH STREET, SANTA MONICA CA 90402